Genmab A/S
GMABGenmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.
Drugs in Pipeline
25
Phase 3 Programs
13
Upcoming Catalysts
6
Next Catalyst
Aug 6, 2026
4wMarket Overview
Stock performance and key metrics
6 upcoming, 1 past
How GMAB's past catalysts played out
Cyclophosphamide
Diffuse Large B-Cell Lymphoma
Pembrolizumab
Non Small Cell Lung Cancer Metastatic
Prednisone
Follicular Lymphoma (FL)
Paclitaxel
Platinum-resistant Ovarian Cancer
Zalutumumab
Head and Neck Cancer
Epcoritamab
Diffuse Large B-Cell Lymphoma
Rina-S
Endometrial Cancer
Oxaliplatin
Diffuse Large B-Cell Lymphoma
Docetaxel
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Investigator's Choice Chemotherapy
Diffuse Large B-Cell Lymphoma
Acasunlimab
Cutaneous Melanoma
Lenalidomide
Diffuse Large B-Cell Lymphoma
Doxorubicin
B-Cell Non-Hodgkin Lymphoma
HuMax-CD4
Cutaneous T-Cell Lymphoma
Venetoclax
Relapsed/Refractory Chronic Lymphocytic Leukemia
Acasunlimab in combination with docetaxel (in a single expansion cohort)
Solid Tumors
gemcitabine and oxaliplatin
Diffuse Large B-Cell Lymphoma
GEN1286
Advanced Solid Tumor
GEN1042
Malignant Solid Tumor
Carboplatin
High Grade Epithelial Ovarian Cancer
tisotumab vedotin
Solid Tumor
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Breast Cancer, Breast Neoplasms
Ibrutinib
Non-Hodgkin Lymphoma
Enapotamab vedotin (HuMax-AXL-ADC)
Ovarian Cancer
Epcoritamab (monotherapy)
Diffuse Large B Cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cyclophosphamide | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Pembrolizumab | Phase 3 | Non Small Cell Lung Cancer Metastatic | - | - |
Prednisone | Phase 3 | Follicular Lymphoma (FL) | - | - |
Paclitaxel | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
Zalutumumab | Phase 3 | Head and Neck Cancer | - | - |
Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Rina-S | Phase 3 | Endometrial Cancer | - | - |
Oxaliplatin | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Docetaxel | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | - | - |
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Acasunlimab | Phase 3 | Cutaneous Melanoma | - | - |
Lenalidomide | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Doxorubicin | Phase 3 | B-Cell Non-Hodgkin Lymphoma | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Venetoclax | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia | - | - |
Acasunlimab in combination with docetaxel (in a single expansion cohort) | Phase 2 | Solid Tumors | - | - |
gemcitabine and oxaliplatin | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
GEN1286 | Phase 2 | Advanced Solid Tumor | - | - |
GEN1042 | Phase 2 | Malignant Solid Tumor | - | - |
Carboplatin | Phase 2 | High Grade Epithelial Ovarian Cancer | - | - |
tisotumab vedotin | Phase 2 | Solid Tumor | - | - |
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Phase 2 | Breast Cancer, Breast Neoplasms | - | - |
Ibrutinib | Phase 2 | Non-Hodgkin Lymphoma | - | - |
Enapotamab vedotin (HuMax-AXL-ADC) | Phase 2 | Ovarian Cancer | - | - |
Epcoritamab (monotherapy) | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Genmab A/S's drug pipeline?→
CatalystAlert tracks 25 drug candidates in Genmab A/S's (GMAB) pipeline across Phase 3, Phase 2. Its lead program is Cyclophosphamide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genmab A/S's next FDA catalyst?→
Genmab A/S's (GMAB) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GMAB biotech catalysts?→
Add GMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genmab A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.